Highlights
- CU6 shares closed at $2.39, down 3.63% on 24 August 2026
- Reported encouraging early clinical data from its SECuRE trial evaluating 67Cu-SAR-bisPSMA in prostate cancer
- At the 8 GBq dose level, preliminary assessment showed two additional complete responses
- SAR-bisPSMA is the company's leading prostate-cancer program
Clarity Pharmaceuticals Ltd (ASX:CU6) shares closed at $2.39, down 3.63% on 24 August 2026. The stock remains one to watch as the clinical-stage radiopharmaceutical company continues to build clinical evidence for its targeted approach to prostate cancer through its SECuRE trial.
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing copper-based diagnostic and therapeutic products designed to target and treat cancer. The company's technology platform is built around the use of copper isotopes attached to targeting molecules that can identify and bind to specific markers expressed by cancer cells, enabling both precise diagnostic imaging and targeted therapeutic delivery. Clarity's leading program, SAR-bisPSMA, is focused on prostate cancer, one of the most common cancers affecting men globally, and reflects the growing clinical interest in radiopharmaceutical approaches that combine diagnostic and therapeutic capabilities within a single targeted platform. As a clinical-stage company, Clarity's progress is measured through the accumulation of clinical trial data across its various development programs, with successful outcomes serving as key catalysts for both scientific validation and potential future regulatory approval. The company operates within a rapidly growing segment of oncology, as radiopharmaceuticals increasingly gain recognition for their ability to deliver more precise and effective cancer treatment compared to some conventional therapeutic approaches.
Key Developments
Clarity Pharmaceuticals recently reported encouraging early clinical data from its SECuRE trial evaluating 67Cu-SAR-bisPSMA in prostate cancer, providing further clinical evidence in support of the company's targeted radiopharmaceutical platform. At the 8 GBq dose level, preliminary assessment showed two additional complete responses, adding to the accumulating body of evidence supporting Clarity's approach and reinforcing the potential clinical benefit of the therapy at this dose level. The company is developing copper-based radiopharmaceuticals designed to both diagnose and treat cancer, with SAR-bisPSMA representing its leading prostate-cancer program and the primary focus of current clinical development efforts. The August update is significant because additional complete responses could strengthen the clinical rationale for advancing the treatment through further stages of development, potentially supporting progression toward larger or later-stage trials. Further patient follow-up and additional clinical data will be important in determining the program's future development path, as regulators and clinicians will typically require a larger and more mature dataset before the full clinical significance of these early complete responses can be properly assessed. Investors will continue to monitor upcoming data releases as the trial progresses.
Conclusion
Clarity Pharmaceuticals's latest SECuRE trial data, showing additional complete responses at the 8 GBq dose level, adds further weight to the clinical case for its copper-based SAR-bisPSMA program in prostate cancer. While the share price declined on the day, the underlying clinical progress continues to build a stronger evidence base for the therapy. Ongoing patient follow-up and further data releases will be important in determining the next steps for this leading program within Clarity's radiopharmaceutical pipeline.
_11_17_2026_06_50_14_402066.jpg)





Please wait processing your request...